Overview of Wondfo in the First Half of 2021

In 2020, the whole external diagnosis industry was greatly increased due to the large volume of COVID-19 business. The market was particularly concerned about the planning of IVD enterprises after the outbreak. As the first share of POCT in China, Wondfo will continue to be driven by innovation and cooperation in 2021, implement both epidemic business, conventional business, and double-cycle in domestic and abroad.

On March 26, the meeting of “Cultivate New Opportunities” was grandly held in Chongqing by Wondfo with more than 1000 partners.

On April 23, WondfoCartis, a subsidiary of Wondfo, signed a memorandum of strategic cooperation with AstraZeneca to build a county medical ecosystem.

On May 12, Wondfo officially signed a contract with Bio Island Laboratory to jointly build the " POCT Transformation Research Center of Bio Island laboratory Real-time Detection ".

In May 21st, Wondfo won the bid of antigen detection kit for COVID-19 announced by Guangdong drug exchange center on the selection of New Coronavirus (2019-nCoV) reagent alliance from regional group purchasing information.

On June 25, Wondfo won the patent of "Testing and Determination Equipment and Methods" of the 22nd China Patent Excellence Award.

As a company with global business layout, Wondfo will adhere to the concept of "Racing for life", continue to strengthen scientific and technological innovation, accelerate the industrialization of innovation achievements, and jointly promote the realization of the goal of "Healthy China 2030".